# US 2017/0253566 A1 · Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253566 A1
- Document ID: US20170253566A1
- Status: Published application
- Kind: A1
- Application number: 15/510,758
- Filed: 2015-09-14
- Published: 2017-09-07
- Earliest claimed: 2014-09-16
- Assignees: Shenzhen Chipscreen Biosciences Co., Ltd.
- Applicants: Shenzhen Chipscreen Biosciences, Ltd.
- Inventors: Xianping LU; Jindi YU; Qianjiao YANG; Zhibin LI; Desi PAN; Song SHAN; Jiangfei ZHU; Xianghui WANG; Xiangheng LIU; Zhiqiang NING
- Web page: https://patentgrep.com/patent/US20170253566A1

## CPC

- C07D 239/48: Two nitrogen atoms
- A61K 31/33: Heterocyclic compounds
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An application of a compound having general formula (I) as JAK3 and/or JAK1 kinase and a preparation method for the compound.

## Claims

### Claim 1

A compound of general formula (I),
or a pro-drug, stereoisomer, pharmaceutically acceptable salt or hydrate thereof,
wherein,
R1 is halogen or C1-C6 alkyl;
R2 is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylcarbonyl and C1-C6 alkylamino;
R3 is hydrogen or halogen;
R4 is hydrogen or C1-C4 alkyl;
X is NH, O or S;
Y is CO or S(O)2;
Z is a covalent bond, CH2 or (CH2)2;
n is an integer from 1 to 4; and
Ring A is a benzene ring, pyridine ring or piperidine ring.

### Claim 2 (depends on 1)

The compound of general formula (I) according to claim 1, wherein:
R1 is halogen or C1-C6 alkyl;
R2 is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, fluoro, methyl, ethyl, methoxyl, difluoromethyl, trifluoromethyl, acetyl and dimethylamino;
R3 is hydrogen or halogen;
R4 is hydrogen or methyl;
X is NH or O;
Y is CO or S(O)2;
Z is a covalent bond, CH2 or (CH2)2;
n is an integer from 1 to 4; and
Ring A is a benzene ring, pyridine ring or piperidine ring.

### Claim 3 (depends on 1)

The compound of general formula (I) according to claim 1, wherein:
R1 is halogen or C1-C6 alkyl;
R2 is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, fluoro, methyl, ethyl, methoxyl, difluoromethyl, trifluoromethyl, acetyl and dimethylamino;
R3 is hydrogen or fluoro;
R4 is methyl;
X is NH;
Y is CO;
Z is a covalent bond;
n is an integer from 1 to 4; and
Ring A is a benzene ring, pyridine ring.

### Claim 4 (depends on 1)

The compound of general formula (I) according to claim 1, wherein:
R1 is chloro, fluoro or methyl;
R2 is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, fluoro, methyl, ethyl, methoxyl, difluoromethyl, trifluoromethyl, acetyl and dimethylamino;
R3 is hydrogen or fluoro;
R4 is methyl;
X is NH;
Y is CO;
Z is a covalent bond;
n is an integer from 1 to 4; and
Ring A is a benzene ring.

### Claim 5 (depends on 1)

The compound of general formula (I) according to claim 1, wherein:
R1 is chloro;
R2 is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, fluoro, methyl, ethyl, methoxyl, difluoromethyl, trifluoromethyl, acetyl and dimethylamino;
R3 is hydrogen or fluoro;
R4 is methyl;
X is NH;
Y is CO;
Z is a covalent bond;
n is an integer from 1 to 4; and
Ring A is a benzene ring.

### Claim 6 (depends on 1)

The compound of general formula (I) according to claim 1, wherein:
R1 is chloro;
R2 is one or more substituents selected from the group consisting of cyano, fluoro and trifluoromethyl;
R3 is hydrogen or fluoro;
R4 is methyl;
X is NH;
Y is CO;
Z is a covalent bond;
n=1; and
Ring A is a benzene ring.

### Claim 7 (depends on 1)

The compound of general formula (I) according to claim 1, wherein:
R1 is chloro;
R2 is one or more substituents selected from the group consisting of cyano;
R3 is hydrogen or fluoro;
R4 is methyl;
X is NH;
Y is CO;
Z is a covalent bond;
n=1; and
Ring A is a benzene ring.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein the compound is selected from the group consisting of:
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-cyanobenzamide;
N-(3-(2-(3-acrylamido-4-fluoro-phenylamino)-5-chloropyrimidinyl-4-amino)propyl)-4-trifluoromethylbenzamide;
N-(3-(2-(3-acrylamido-4-fluoro-phenylamino)-5-chloropyrimidinyl-4-amino)propyl)-4-fluorobenzamide;
4-fluoro-N-(3-(2-(4-fluoro-3-(N-methylacrylamido)phenylamino)-5-methylpyrimidinyl-4-amino)propyl)benzamide;
N-(3-(2-(4-fluoro-3-(N-methylacrylamido)phenylamino)-5-methylpyrimidinyl-4-amino)propyl)-4-trifluoromethylbenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-trifluoromethylbenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-fluorobenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-1-methylpiperidinyl-4-formamide;
N-(3-(2-(3-acrylamido-4-fluorophenylamino)-5-chloropyrimidinyl-4-amino)propyl)-4-cyanobenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-dimethylaminobenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-2, 4, 6-trifluorobenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-methoxylbenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-6-cyanonicotinamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-hydroxybenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-cyano-2-fluorobenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-cyano-3-fluorobenzamide;
4-cyano-N-(3-(2-(4-fluoro-3-(N-methylacrylamido)phenylamino)-5-methylpyrimidinyl-4-amino)propyl)-benzamide;
4-cyano-N-(3-(5-fluoro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)benzamide;
N-(5-(5-chloro-4-(3-(2-(4-cyanophenyl)acetamino)propylamino)pyrimidinyl-2-amido)-2-fluorophenyl)-N-methylacryloyl;
N-(5-(5-chloro-4-(3-(4-cyanophenylsulfonamino)propylamino)pyrimidinyl-2-amido)-2-fluorophenyl)-N-methylacryloyl;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-oxo)propyl)-4-cyanobenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-isonicotinamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-ethylbenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-methylbenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)benzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-3-trifluoromethylbenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-3-cyanobenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-3-fluoro-4-trifluoromethylbenzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-2, 3, 4, 5-tetrafluorobenzamide;
4-acetyl-N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)benzamide;
N-(3-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)propyl)-4-difluoromethylbenzamide; and
N-(6-(5-chloro-2-(4-fluoro-3-(N-methylacrylamido)phenylamino)pyrimidinyl-4-amino)hexyl)-4-cyanobenzamide;

### Claim 9 (depends on 1)

A method for preparing the compound of general formula (I) according to claim 1, comprising reacting a compound of general formula (IV)
with a compound of general formula (V)
under organic solvent and a catalyst to form the compound of general formula (I), wherein
R1 is halogen or C1-C6 alkyl;
R2 is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylcarbonyl and C1-C6 alkyl amino;
R3 is hydrogen or halogen;
R4 is hydrogen or C1-C4 alkyl;
X is NH, O or S;
Y is CO or S(O)2;
Z is a covalent bond, CH2 or (CH2)2;
n is an integer from 1 to 4; and
ring A is a benzene ring, pyridine ring or piperidine ring.

### Claim 10 (depends on 9)

The preparation method according to claim 9, wherein the catalyst is selected from the group consisting of trifluoroacetic acid, hydrochloric acid and methanesulfonic acid.

### Claim 11 (depends on 9)

The preparation method according to claim 9, wherein the organic solvent is selected from the group consisting of isopropanol and n-butanol.

### Claim 12

A method for preparing a compound of general formula (IV),
comprising reacting a compound of general formula (III)
with a compound of general formula (II)
under organic solvent and an alkali to form the compound of general formula (IV), wherein
R1 is halogen or C1-C6 alkyl;
R2 is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylcarbonyl and C1-C6 alkyl amino;
X is NH or O;
Y is CO or S(O)2;
Z is a covalent bond, CH2 or (CH2)2;
n is an integer from 1 to 4; and
ring A is a benzene ring, pyridine ring or piperidine ring.

### Claim 13 (depends on 12)

The preparation method according to claim 12, wherein the alkali is selected from the group consisting of triethylamine and diisopropylethylamine.

### Claim 14 (depends on 9)

The preparation method according to claim 9, wherein the organic solvent is selected from the group consisting of ethanol, methanol and n-butanol.

### Claim 15 (depends on 1)

A pharmaceutical composition for the treatment of diseases related to abnormal activities of JAK3 and/or JAK1 kinases, comprising the compound of general formula (I) according to claim 1 as the active ingredient and a pharmaceutically acceptable carrier, adjuvant or diluent.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, which is in the form of tablet, capsule, powder, syrup, liquor, suspension, injection or ointment.

### Claim 17 (depends on 1)

Use of the compound according to claim 1 in the preparation of a medicament for the treatment or prevention of autoimmune diseases, inflammatory diseases, cancers, myeloproliferative diseases, bone resorption diseases or graft-versus-host diseases.

### Claim 18 (depends on 1)

Use of the compound according to claim 1 in the preparation of a medicament for the treatment or prevention of rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukaemia, and lymphoma.

### Claim 19 (depends on 15)

Use of the pharmaceutical composition according to claim 15 in the preparation of a medicament for the treatment or prevention of autoimmune diseases, inflammatory diseases, cancers, myeloproliferative diseases, bone resorption diseases and graft-versus-host diseases.

### Claim 20 (depends on 15)

Use of the pharmaceutical composition according to claim 15 in the preparation of a medicament for the treatment or prevention of rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukaemia, and lymphoma.

### Claim 21 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the formulation thereof has a unit dosage ranging from 0.0001 to 200 mg.
